Risk factors for high erythropoiesis stimulating agent resistance index in pre-dialysis chronic kidney disease patients, stages 4 and 5

International Urology and Nephrology

Volumn 43, Issue 3, 2011, Pages 835-840

  De Lurdes Agostinho Cabrita, Ana ^a   Pinho, Ana ^a   Malho, Anabela ^a   Morgado, Elsa ^a   Faísca, Marília ^a   Carrasqueira, Hermínio ^a   Silva, Ana Paula ^a   Neves, Pedro Leäo ^a  

^a HOSPITAL DE FARO   (Portugal)

Author keywords

Anemia; Erythropoiesis stimulating agent resistance; Inflammation; Malnutrition

Indexed keywords

ANTIANEMIC AGENT; CALCIUM; FERRITIN; INTERLEUKIN 6; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PHOSPHATE; TUMOR NECROSIS FACTOR ALPHA;

AGED; ANEMIA; ARTICLE; BLOOD SAMPLING; CALCIUM BLOOD LEVEL; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; MULTIPLE REGRESSION; NUTRITIONAL ASSESSMENT; NUTRITIONAL STATUS; PHOSPHATE BLOOD LEVEL; PROTEIN BLOOD LEVEL; RISK FACTOR; SEX DIFFERENCE; SUBJECTIVE GLOBAL NUTRITIONAL ASSESSMENT;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANEMIA; CARDIOVASCULAR DISEASES; CHI-SQUARE DISTRIBUTION; DRUG RESISTANCE; ERYTHROPOIETIN; FEMALE; FERRITINS; GLOMERULAR FILTRATION RATE; HEMATINICS; HEMOGLOBINS; HUMANS; INFLAMMATION; INTERLEUKIN-6; KIDNEY FAILURE, CHRONIC; LOGISTIC MODELS; MALE; MALNUTRITION; MIDDLE AGED; RISK FACTORS; SEX FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80555143134     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-010-9805-9     Document Type: Article

References (44)

1. Eschbach JW, Adamson JW (1985) Anemia of end-stage renal disease. Kidney Int 28:1-5
2. Winearls CG, Oliver DO, Pippard MJ et al (1986) Effect of human erythropoietin derived from recombinant DNA on the anemia of patients maintained by chronic hemodialysis. Lancet 2:1175-1177 (Pubitemid 17179038)
3. Eschbach JW, Egrie JC, Downing MR et al (1987) Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: Results of phase I and II clinical trial. N Engl J Med 316:73-78 (Pubitemid 17052741)
4. Wingard RL, Parker RA, Ismail L et al (1995) Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. Am J Kidney Dis 25:433-439
5. Silverberg DS, Wexler D, Blum M et al (2003) The cardiorenal anaemia syndrome: Does it exist? Nephrol Dial Transplant 18(Suppl 8):viii7-viii12 (Pubitemid 37509094)
6. Collins AJ, Li S, Peter W et al (2001) Death, hospitalization and economic associations among incident haemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 12:2465-2473 (Pubitemid 33021125)
7. Foley RN (2002) Anaemia: Cardiovascular adaptations and maladaptative responses in chronic kidney disease. Nephrol Dial Transplant 17(Suppl 11):32-34 (Pubitemid 35277061)
8. Astor BC, Coresh J, Heiss G et al (2006) Kidney function and anemia as risk factors for coronary heart disease and mortality: The Atherosclerosis Risk in Communities (ARIC) study. Am Heart J 151:492-500 (Pubitemid 43144756)
9. Leeder SR, Mitchell P, Liew G et al (2006) Low hemoglobin, chronic kidney disease, and risk for coronary heart disease-related death: The Blue Mountains Eye study. J Am Soc Nephrol 17:279-288
10. Tong EM, Nisseson AR (2001) Erythropoietin and anemia. Semin Nephrol 21:190-203 (Pubitemid 32232975)
11. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Section IV (2004) Failure to respond to treatment. Nephrol Dial Transplant 19(suppl 2):ii32-ii36
12. Macdougall IC, Cooper AC (2002) Erythropoietin resistance: The role of inflammation and pro-inflammatory cytokines. Nephrol Dial Transplant 17(Suppl 11):39-43 (Pubitemid 35277063)
13. Stenvinkel P (2003) Anaemia and inflammation: What are the implications for the nephrologists? Nephrol Dial Transplant 18(Suppl 8):viii17-viii22 (Pubitemid 37509096)
14. Kalantar-Zadeh K, Ikizler TA, Block G et al (2003) Malnutrition- inflammation complex syndrome in dialysis patients: Causes and consequences. Am J Kidney Dis 42:864-881 (Pubitemid 37322905)
15. Neves PL, Morgado E, Faísca M et al (2006) Nutritional and inflammatory status influence darbepoietin dose in predialysis elderly patients. Int Urol Nephrol 38:811-813 (Pubitemid 46336046)
16. Kanbay M, Perazella MA, Kasapoglu B et al (2010) Erythropoiesis stimulatory agent-resistant anemia in dialysis patients: Review of causes and management. Blood Purif 29(1):1-12
17. Cotter DJ, Stefanik K, Zhang Y et al (2004) Hematocrit was not validated as a surrogate end point for survival among epoietin-treated hemodialysis patients. J Clin Epidemiol 57:1086-1095 (Pubitemid 39446648)
18. Zhang Y, Thamer M, Stefanik K et al (2004) Epoietin requirements predict mortality in hemodialysis patients. Am J Kidney Dis 44:866-876 (Pubitemid 39445919)
19. Regidor DL, Kopple JD, Kovesdy CP et al (2006) Associations between changes in hemoglobin and administerederythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 17:1181-1191
20. Lopez-Gomez JM, Porto J, Aljama P (2008) Factors that condition the response to erythropoeitin in patients on hemodialysis and their relation to mortality. Kidney Int 74:S75-S81
21. Levey AS, Bosch JP, Lewis JB et al (1999) A more accurate method to estimate glomerular filtration rate from serum craetinine: A new prediction equation. Ann Intern Med 130:461-470 (Pubitemid 29135798)
22. Hsu C, McCulloch CE, Curhan GC (2002) Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: Results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 13:504-510 (Pubitemid 34106294)
23. Sarnak MJ, Tighiouart H, Guruprasad M et al (2002) Anemia as a risk factor for cardiovascular disease in the Atherosclerosis Risk in Communities (ARIC) study. J Am Coll Cardiol 40:27-33 (Pubitemid 34701373)
24. Kuriyama S, Tomonari H, Yoshida H et al (1997) Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in non diabetic patients. Nephron 77:176-185 (Pubitemid 27440408)
25. Neves PL, Morgado E, Baptista A et al (2007) Anaemia and interleukin-6 are associated with a faster progression to end-stage renal disease. Dial Transplant 36:445-456
26. Jungers P, Choukroun G, Oualin Z et al (2001) Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant 16:307-312 (Pubitemid 32123919)
27. Lim VS, DeGowin RL, Zavala D et al (1989) Recombinant human erythropoietin treatment in predialysis patients. A double-blind placebo-controlled trial. Ann Intern Med 110:108-114 (Pubitemid 19033195)
28. Revicki DA, Brown RE, Feeny DH et al (1995) Healthrelated quality of life associated with recombinant human erythropoietin therapy in predialysis chronic renal disease patients. Am J Kidney Dis 25:548-554
29. Fink J, Blahut S, Reddy M et al (2001) Use of erythropoietin before the initiation of dialysis and its impact on mortality. Am J Kidney Dis 37:348-355 (Pubitemid 32116028)
30. Maddux FW (2007) Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease. Ann Pharmacother 41:1761-1769 (Pubitemid 350044337)
31. Drueke TB, Locatelli F, Clyne N et al (2006) Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355(20):2071-2084 (Pubitemid 44749316)
32. Singh AK, Szczech L, Tang KL et al (2006) Correction of anemia with epoietin alfa in chronic kidney disease. N Engl J Med 355:2085-2098 (Pubitemid 44749317)
33. Pfeffer MA, Burdmann EA, Chen CY et al (2009) A trial of darbepoietin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361:2019-2032
34. Locatelli F, Andrulli S, Memoli B et al (2006) Nutritionalinflammation status and resistance to erythropoietin therapy in hemodialysis patients. Nephrol Dial Transplant 21:991-998
35. Barany P, Divino Filho JC, Bergstrom J (1997) High C-reactive protein is a strong predictor of resistance to erythropoeitin in hemodialysis patients. Am J Kidney Dis 29:565-568 (Pubitemid 27155278)
36. Wei M, Bargman JM, Oreopoulus DG (2007) Factors related to erythropoietin hypo-responsiveness in patients on chronic peritoneal dialysis. Int Urol Nephrol 39(3): 935-940 (Pubitemid 47365410)
37. Stenvinkel P, Barany P (2002) Anaemia, rHuEPO resistance, and cardiovascular disease in end-stage renal failure: Links to inflammation and oxidative stress. Nephrol Dial Transplant 17(suppl 5):32-37 (Pubitemid 34823070)
38. Stenvinkel P, Heimbürger O, Lindholm B et al (2000) Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol Dial Transplant 15:953-960 (Pubitemid 30410364)
39. Kalantar-Zadeh K, Block G, McAllister CJ et al (2004) Appetite and inflammation, nutrition, anemia, and clinical outcome in hemodialysis patients. Am J Clin Nutr 80: 297-307
40. McKevitt PM, Jones JF, Lane DA et al (1990) The elderly on dialysis. Some considerations in compliance. Am J Kidney Dis 16:346-350 (Pubitemid 20377357)
41. Bonanno G, Urso S, Lo Faro F et al (1996) Parathyroid hormone in a population of elderly patients on hemodialysis (preliminary data). Arch Gerontol Geriatr 22:441-445
42. Di lorio B, Stellato D, De Santo N et al (2004) Association of gender and age with erythropoietin resistance in hemodialysis patients: Role of menstrual status. Blood Purif 22:423-427 (Pubitemid 39551752)
43. Ifudu O, Uribarri J, Rajwani I et al (2001) Gender modulates responsiveness to recombinant erythropoietin. Am J Kidney Dis 38:518-522 (Pubitemid 32803062)
44. Bamgbola OF, Kaskel FJ, Coco M (2009) Analyses of age, gender and other risk factors of EPO resistance in pediatric and adult dialysis cohorts. Pediatr Nephrol 24:571-579